Periodic Reporting for period 1 - CureGLIO (Clinical validation of GLIX1: a small molecule that targets epigenetic changes in cancer cells to treat glioblastoma multiforme (GBM), the highest global unmet need in oncology.)

The prognosis of glioblastoma (GBM) is exceedingly poor. Even with the best available treatment options, a patient is expected to live 16.5 months on average. The front-line drug, Temozolomide (TMZ), improves lifespan by a mere 2.5 months. However, between 50-75% of these...